AACR 2020: IL-15 Superagotic SO-C101 shows strong anti-tumor effect

At the 2020 American Association for Cancer Research (AACR) online meeting, SOTIO and Cytune Pharma announced IL-15 superagotics SO-C101 as a monotherapy, or in conjunction with PD-1 inhibitors, to treat a wide range of tumors in preclinical experimental data"SO-C101, as an IL-15 receptor b/g superagotic, has the ability to mobilize NK cells and CD8-Plus T cells to act as anti-tumor, and preclinical data demonstrate that SO-C101 can regulate NK cells and CD8 plus T cells in combination with monodrug therapy to reduce andprevent tumor growthin a variety of mouse models," said soTIO Executive Officer"
" We look forward to completing dose confirmation for phase 1b single drug therapy for advanced solid tumors by the end of the year and starting joint use with PD-1 monoantitruda in the summer of 2020"
research data are as follows:SO-C101 monotherapy reduces tumor development and growth rate in the TC-1 mouse tumor model (a lung cancer model) in a NK and CD8-T cell-dependent mannerSO-C101 monotherapy induces the proliferation and diffusion ofimmunecells in tumors, lymph nodes and spleen, and activates NK and CD8 plus T cytotoxic genes in TC-1 mouse tumorsSO-C101 monotherapy reduces tumor growth in the TRAMP-C2 mouse tumor model (a prostate cancer model) and increases the number of CD8 plus T-cells and NK cells, but does not amplify regulatory T cellsSO-C101 binding PD-1 inhibitors prevent tumor development in TRAMP-C2 mice and delay tumor growth when tumor cells are re-vaccinatedSO-C101's intermediation-mediated anti-tumor response in the TRAMP-C2 tumor model and its combination with PD-1 inhibitors depend mainly on NK and CD8 plus T cells